Last reviewed · How we verify

NCT04712786

Refractive Changes Following Vitrectomy

Completed Last updated 15 January 2021
What this trial tests

trial testing pars plana vitrectomy in Retinal Detachment in 47 participants. Completed in 27 December 2020.

Timeline
1 December 2020
Primary endpoint
25 December 2020
27 December 2020

Quick facts

Lead sponsorBursa Retina Eye Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment47
Start date1 December 2020
Primary completion25 December 2020
Estimated completion27 December 2020
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Bursa Retina Eye Hospital

Who can join

18 and older, any sex, with Retinal Detachment or Refractive Errors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

We aimed o compare the refractive changes associated with pars plana vitrectomy with or without intraocular gas tamponade in pseudophakic eyes. This retrospective study included pseudophakic patients with Nd:YAG laser posterior capsulotomy who underwent 23G PPV between February 2015 and March 2019. Group 1 consisted of patients with regmatogenous RD who underwent PPV and 12% perflouropropane (C3F8) gas tamponade whereas Group 2 consisted of patients who underwent PPV for epiretinal membrane or vitreous hemorrhage (VH). No tamponade was used in Group 2. Minimum follow-up was 12 months.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of pars plana vitrectomy

Trials testing the same drug.

Other recruiting trials for Retinal Detachment

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04712786.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing